BioCentury | Jul 29, 2013
Company News

Vivus board of directors update

...Mountain View, Calif. Business: Endocrine/Metabolic Appointed: Michael Astrue as chairman, formerly president and CEO of Transkaryotic Therapies Inc....
BioCentury | Jul 24, 2013
Company News

Vivus names Astrue chairman, Zook CEO

...a proxy battle with activist investor First Manhattan Co. Astrue, former president and CEO at Transkaryotic Therapies Inc....
...from First Manhattan that will join four existing Vivus directors alongside a newly reconstituted board. Transkaryotic...
BioCentury | Jul 22, 2013
Finance

Qsymia sera

...Medicines Evaluation Unit. Also in the slate are Michael Astrue, former president and CEO at Transkaryotic Therapies Inc....
BioCentury | May 20, 2013
Finance

Striking similarity

...Samuel Colin, Michael Astrue, Jon Biro and Herm Rosenman. Astrue was president and CEO at Transkaryotic Therapies Inc....
BioCentury | May 20, 2013
Strategy

R&D rewind

...give the company more reason to do its own R&D. For example, when Shire acquired Transkaryotic Therapies Inc....
...ERT) for Fabry's disease, as well as Transkaryotic's Gene Activation technology. Since the deal, the Transkaryotic...
BioCentury | Mar 11, 2013
Company News

Vivus endocrine/metabolic news

...include Michael Astrue, formerly interim CEO at Epix Pharmaceuticals Inc. and president and CEO at Transkaryotic Therapies Inc....
BioCentury | Mar 11, 2013
Finance

Manhattan's men

...Biro , John Kastelein, David Norton and Herm Rosenman. Astrue was president and CEO at Transkaryotic Therapies Inc....
BioCentury | Mar 9, 2013
Company News

FMC wants new Vivus board, strategy

...include Michael Astrue, formerly interim CEO at Epix Pharmaceuticals Inc. and president and CEO at Transkaryotic Therapies Inc....
BioCentury | Nov 5, 2012
Strategy

Orphanage in Asia

...Genzyme's last Asia-specific deal was in 2003 when it in-licensed rights to Elaprase idursulfase from Transkaryotic Therapies Inc....
BioCentury | Oct 29, 2012
Company News

Alnylam, Sanofi deal

...deal involving rights only in Japan and the Asia-Pacific region since a 2003 deal with Transkaryotic Therapies Inc....
...for a mucopolysaccharidosis II (MPS-II, Hunter syndrome) therapy. Shire plc (LSE:SHP; NASDAQ:SHPG, London, U.K.) acquired Transkaryotic...
Items per page:
1 - 10 of 552
BioCentury | Jul 29, 2013
Company News

Vivus board of directors update

...Mountain View, Calif. Business: Endocrine/Metabolic Appointed: Michael Astrue as chairman, formerly president and CEO of Transkaryotic Therapies Inc....
BioCentury | Jul 24, 2013
Company News

Vivus names Astrue chairman, Zook CEO

...a proxy battle with activist investor First Manhattan Co. Astrue, former president and CEO at Transkaryotic Therapies Inc....
...from First Manhattan that will join four existing Vivus directors alongside a newly reconstituted board. Transkaryotic...
BioCentury | Jul 22, 2013
Finance

Qsymia sera

...Medicines Evaluation Unit. Also in the slate are Michael Astrue, former president and CEO at Transkaryotic Therapies Inc....
BioCentury | May 20, 2013
Finance

Striking similarity

...Samuel Colin, Michael Astrue, Jon Biro and Herm Rosenman. Astrue was president and CEO at Transkaryotic Therapies Inc....
BioCentury | May 20, 2013
Strategy

R&D rewind

...give the company more reason to do its own R&D. For example, when Shire acquired Transkaryotic Therapies Inc....
...ERT) for Fabry's disease, as well as Transkaryotic's Gene Activation technology. Since the deal, the Transkaryotic...
BioCentury | Mar 11, 2013
Company News

Vivus endocrine/metabolic news

...include Michael Astrue, formerly interim CEO at Epix Pharmaceuticals Inc. and president and CEO at Transkaryotic Therapies Inc....
BioCentury | Mar 11, 2013
Finance

Manhattan's men

...Biro , John Kastelein, David Norton and Herm Rosenman. Astrue was president and CEO at Transkaryotic Therapies Inc....
BioCentury | Mar 9, 2013
Company News

FMC wants new Vivus board, strategy

...include Michael Astrue, formerly interim CEO at Epix Pharmaceuticals Inc. and president and CEO at Transkaryotic Therapies Inc....
BioCentury | Nov 5, 2012
Strategy

Orphanage in Asia

...Genzyme's last Asia-specific deal was in 2003 when it in-licensed rights to Elaprase idursulfase from Transkaryotic Therapies Inc....
BioCentury | Oct 29, 2012
Company News

Alnylam, Sanofi deal

...deal involving rights only in Japan and the Asia-Pacific region since a 2003 deal with Transkaryotic Therapies Inc....
...for a mucopolysaccharidosis II (MPS-II, Hunter syndrome) therapy. Shire plc (LSE:SHP; NASDAQ:SHPG, London, U.K.) acquired Transkaryotic...
Items per page:
1 - 10 of 552